Multiple myeloma will account for an estimated 16,570 new cancer cases in the United States in 2006, with an estimated 11,310 deaths. It is not currently considered curable; however, treatment has evolved rapidly because of new drugs such as bortezomib, thalidomide, and lenalidomide. In addition, increased understanding of the bone marrow microenvironment is creating rationale for new combinations and new drug development. Important updates in the 2007 NCCN guidelines include new recommended single-agent and combination regimens for consideration for induction and salvage therapy.
For the most recent version of the guidelines, please visit NCCN.org
If the inline PDF is not rendering correctly, you can download the PDF file here.
Huntsman Cancer Institute (HCI; huntsmancancer.org) at the University of Utah is the only NCI-designated cancer center in the Intermountain West, serving Utah, Nevada, Idaho, Montana, and Wyoming. HCI acts as steward of the Utah Population Database, the largest genetic database in the world. This resource was pivotal in the discovery of several genes implicated in cancer, including BRCA1, BRCA2, APC, and p16. HCI research includes laboratory studies, clinical research, and population studies. HCI's 50-bed cancer specialty hospital and outpatient clinics provide patient care using a multidisciplinary approach to diagnosis and treatment. HCI is the only cancer research hospital in the country that offers patients a comprehensive fitness program, part of its Wellness Center, which also provides nutritional advice and support groups for cancer patients and their caregivers. Walk-in, telephone, online, and outreach programs provide cancer prevention, screening, and treatment information for patients, their families, and the public.
Executive Director Mary Beckerle, PhD, is a nationally-recognized cell biologist whose HCI laboratory has discovered and characterized pathways that control cell motility, adhesion, and response to environmental cues. She holds the Ralph E. and Willia T. Main Presidential Endowed Chair in Cancer Research at the University of Utah and has served as president of the American Society of Cell Biology.